Treatment efficacy of DNA lipid nanocapsules and DNA multimodular systems after systemic administration in a human glioma model

Journal of Gene Medicine

Volumn 14, Issue 12, 2012, Pages 769-775

  David, Stephanie ^a,b   Montier, Tristan ^d,e,g,h   Carmoy, Nathalie ^d   Resnier, Pauline ^a   Clavreul, Anne ^a,f   Mével, Mathieu ^b   Pitard, Bruno ^b,c   Benoit, Jean Pierre ^a   Passirani, Catherine ^a  

^a UNIVERSITÉ D'ANGERS   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c In Cell Art   (France)

^d UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^e DUMG ^*  (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^h BREST UNIVERSITY HOSPITAL   (France)

Author keywords

GAL DNA MMS DOSP; GDEPT; Gene therapy; in vivo biofluorescene imaging; PEG DNA LNCs; Systemic administration

Indexed keywords

DIOLEYLAMIN SUCCINYL PAROMOMYCIN; GALACTOSE; GANCICLOVIR; HERPES SIMPLEX VIRUS THYMIDINE KINASE; LIPID NANOCAPSULE; LUCIFERASE; MACROGOL; NANOCAPSULE; NANOCARRIER; PLASMID DNA; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; FLUORESCENCE; GLIOMA; HUMAN; IN VIVO STUDY; LIPID COMPOSITION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY EFFECT; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA; FEMALE; GENE TRANSFER TECHNIQUES; GLIOMA; HUMANS; LIPIDS; LIPOSOMES; MICE; MOLECULAR IMAGING; NANOCAPSULES; PLASMIDS; POLYETHYLENE GLYCOLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS; MUS MUSCULUS; SIMPLEXVIRUS;

EID: 84871483251     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2683     Document Type: Article

References (36)

1. Arko L, Katsyv I, Park GE, Luan WP, Park JK. Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther 2010; 128: 1-36.
2. Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumours. Biomaterials 2009; 30: 2302-2318.
3. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
4. Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol Aspects Med 2007; 28: 4-41.
5. Altaner C. Prodrug cancer gene therapy. Cancer Lett 2008; 270: 191-201.
6. Immonen A, Vapalahti M, Tyynela K, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomized, controlled study. Mol Ther 2004; 10: 967-972.
7. Chowdhury EH. Nuclear targeting of viral and non-viral DNA. Expert Opin Drug Deliv 2009; 6: 697-703.
8. Collins SA, Guinn BA, Harrison PT, Scallan MF, O'Sullivan GC, Tangney M. Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther 2008; 8: 66-78.
9. Jin S, Ye K. Nanoparticle-mediated drug delivery and gene therapy. Biotechnol Prog 2007; 23: 32-41.
10. Kreiss P, Cameron B, Rangara R, et al. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res 1999; 27: 3792-3798.
11. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008; 29: 3477-3496.
12. Huynh NT, Roger E, Lautram N, Benoit JP, Passirani C. The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. Nanomedicine (Lond) 2010; 5: 1415-1433.
13. Vonarbourg A, Passirani C, Desigaux L, et al. The encapsulation of DNA molecules within biomimetic lipid nanocapsules. Biomaterials 2009; 30: 3197-3204.
14. Morille M, Passirani C, Dufort S, et al. Tumour transfection after systemic injection of DNA lipid nanocapsules. Biomaterials 2011; 32: 2327-2333.
15. David S, Carmoy N, Resnier P, et al. In vivo imaging of DNA lipid nanocapsules after systemic administration in a melanoma mouse model. Int J Pharm 2012; 423: 108-115.
16. Letrou-Bonneval E, Chevre R, Lambert O, et al. Galactosylated multimodular lipoplexes for specific gene transfer into primary hepatocytes. J Gene Med 2008; 10: 1198-1209.
17. David S, Passirani C, Carmoy N, et al. DNA nanocarriers for systemic administration - characterization and in vivo bioimaging in healthy mice. Mol Ther NA. DOI: 10.1038/mtna.2012.56
18. Billiet L, Gomez JP, Berchel M, et al. Gene transfer by chemical vectors, and endocytosis routes of polyplexes, lipoplexes and lipopolyplexes in a myoblast cell line. Biomaterials 2012; 33: 2980-2990.
19. Desigaux L, Sainlos M, Lambert O, et al. Self-assembled lamellar complexes of siRNA with lipidic aminoglycoside derivatives promote efficient siRNA delivery and interference. Proc Natl Acad Sci USA 2007; 104: 16534-16539.
20. Vigneron JP, Oudrhiri N, Fauquet M, et al. Guanidinium-cholesterol cationic lipids: efficient vectors for the transfection of eukaryotic cells. Proc Natl Acad Sci USA 1996; 93: 9682-9686.
21. Garcion E, Lamprecht A, Heurtault B, et al. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumour progression in rats. Mol Cancer Ther 2006; 5: 1710-1722.
22. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 2002; 19: 875-880.
23. Morille M, Montier T, Legras P, et al. Long-circulating DNA lipid nanocapsules as new vector for passive tumour targeting. Biomaterials 2009; 31: 321-329.
24. Schwartz AL. The hepatic asialoglycoprotein receptor. CRC Crit Rev Biochem 1984; 16: 207-233.
25. Steirer LM, Park EI, Townsend RR, Baenziger JU. The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid alpha2, 6-galactose. J Biol Chem 2009; 284: 3777-3783.
26. Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006; 16: 137R-157R.
27. Rorive S, Belot N, Decaestecker C, et al. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumour astrocytes into the brain parenchyma. Glia 2001; 33: 241-255.
28. Camby I, Decaestecker C, Lefranc F, Kaltner H, Gabius HJ, Kiss R. Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern. Biochem Biophys Res Commun 2005; 335: 27-35.
29. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumour vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-284.
30. Maeda H. The enhanced permeability and retention (EPR) effect in tumour vasculature: the key role of tumour-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189-207.
31. Maatta AM, Samaranayake H, Pikkarainen J, Wirth T, Yla-Herttuala S. Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. Curr Gene Ther 2009; 9: 356-367.
32. Matuskova M, Hlubinova K, Pastorakova A, et al. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett 2009; 290: 58-67.
33. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumours. Science 1992; 256: 1550-1552.
34. Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001; 61: 8743-8750.
35. Soubrane C, Mouawad R, Rixe O, et al. Direct gene transfer of a plasmid carrying the herpes simplex virus-thymidine kinase gene (HSV-TK) in transplanted murine melanoma: in vivo study. Eur J Cancer 1996; 32A: 691-695.
36. Rosolen A, Frascella E, di Francesco C, et al. In vitro and in vivo antitumour effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastoma. Gene Ther 1998; 5: 113-120.